CN101843842B - Medicament for treating hypothyroidism - Google Patents
Medicament for treating hypothyroidism Download PDFInfo
- Publication number
- CN101843842B CN101843842B CN2010102067008A CN201010206700A CN101843842B CN 101843842 B CN101843842 B CN 101843842B CN 2010102067008 A CN2010102067008 A CN 2010102067008A CN 201010206700 A CN201010206700 A CN 201010206700A CN 101843842 B CN101843842 B CN 101843842B
- Authority
- CN
- China
- Prior art keywords
- percent
- hypothyroidism
- examples
- tsh
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 208000003532 hypothyroidism Diseases 0.000 title abstract description 20
- 230000002989 hypothyroidism Effects 0.000 title abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 238000007796 conventional method Methods 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- 241000756943 Codonopsis Species 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 10
- 210000001685 thyroid gland Anatomy 0.000 abstract description 20
- 210000001519 tissue Anatomy 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000007368 endocrine function Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000035790 physiological processes and functions Effects 0.000 abstract description 2
- 239000006188 syrup Substances 0.000 abstract description 2
- 235000020357 syrup Nutrition 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 25
- 206010018498 Goitre Diseases 0.000 description 13
- 201000003872 goiter Diseases 0.000 description 12
- 238000007689 inspection Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000011084 recovery Methods 0.000 description 9
- 206010010774 Constipation Diseases 0.000 description 8
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 7
- 206010020765 hypersomnia Diseases 0.000 description 7
- 239000002023 wood Substances 0.000 description 7
- 208000019790 abdominal distention Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010002942 Apathy Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 230000000849 parathyroid Effects 0.000 description 3
- DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 208000001204 Hashimoto Disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010039840 Secondary hypothyroidism Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000029305 central congenital hypothyroidism Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000007106 menorrhagia Diseases 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- -1 TGAB Chemical compound 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940036571 iodine therapy Drugs 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicament for treating hypothyroidism, which comprises the following raw materials in percentage by weight: 15 to 25 percent of codonopsis pilosula, 15 to 25 percent of astragalus, 25 to 40 percent of honeysuckle flower, 15 to 30 percent of dwarf lilyturf tuber and 10 to 20 percent of common selfheal fruit-spike. The medicament can be oral liquid or decoction or granules, or capsules or tablets or pills or syrup or mixture or powder prepared by conventional method, and can be oral liquid or pills prepared by the conventional pharmaceutical method. The medicament can improve endocrine functions by adjusting immunity of the organism so as to radically treat the hypothyroidism, and makes patients not need taking medicaments all life. The therapy has the advantages of no pain, no side effects, economy and convenience, and makes thyroid gland tissues of patients activated again so as to maintain normal physiological functions.
Description
Technical field: the invention belongs to field of pharmaceutical technology, relate to the hypothyroid medicine of a kind of treatment.
Background technology: hypothyroidism; Be called for short hypothyroidism; The cause of disease is to cause a series of syndromes owing to multiple reason causes parathyroid tissue can not produce enough hormones; Few with fear of cold, antiperspirant clinically, malaise, slow movement, drowsiness, lethargy, hypomnesis etc. are main clinical manifestation.The sickness rate that this is sick, the women is generally 5-8 times of male apparently higher than the male, and most hypothyroidism is to be formed by the chronic lymphocytic thyroiditis development.The patient that major part suffers from hypothyroidism has thyromegaly, parathyroid tissue cirrhosis, clinical manifestations such as the bloated discomfort of local sensation wood.Hypothyroidism regular meeting occurs silently, early stage in this disease, and reason such as a lot of patients are also unconscious, think it is the work overwork by mistake, and pressure is excessive is so be difficult for coming to light in early days.Because the thyroxine hyposecretion has restricted metabolic function, has reduced nerve excitability, also the pale complexion edema due to deficiency too fat to move obesity appears, in regular meeting; Xerosis cutis, thicken, coarse, anorexia abdominal distention, constipation, fatigue and weakness; Resistance descends, and easy catching a cold is apathy, hypomnesis etc.; Myxedema can occur when serious, influence cardiac function, thereby seriously influence patient's work and life, reduce patient's quality of life.If hypothyroidism occurs at juvenile stage, can have a strong impact on its g and D, cause infant mental retardation, symptom such as of short and small stature to occur, cause very big misery to the patient.
The conventional therapy of hypothyroidism is a Hormone Replacement Therapy at present, as using the thyroxin alternative medicine.This method is cured the symptoms, not the disease, and can not fundamentally improve thyroid function, so patient need take thyroxin throughout one's life.Long-term a large amount of hormone therapy often causes corresponding hypothalamus---the feedback suppression of hypophysis target gland axle, and increase the weight of hypofunction, even relevant target gland atrophy, patient then must rely on foreign aid's hormone all the life, makes the person of suffering from very painful.
Summary of the invention: the purpose of this invention is to provide the hypothyroid medicine of a kind of treatment, be used for efficacious therapy hypothyroidism disease, thereby effectively overcome the above-mentioned drawback of existing in prior technology.
The objective of the invention is according to the Radix Codonopsis nature and flavor sweetly, flat, have invigorating middle warmer, QI invigorating, promote the production of body fluid, nourish blood, spleen invigorating, abirritative effect; Radix Codonopsis has excitation to nervous system, but the enhancing body resistance brings high blood pressure down; Increase hematochrome; Enhancing human immune, the activity of raising superoxide dismutase strengthens the ability of eliminating free radical; But Radix Astragali invigorating QI to consolidate the body surface resistance has raise immunity, and enhancing body anoxia enduring and stress ability promote organism metabolism, antibiotic and inhibition virus function; One of Flos Lonicerae system rare Chinese medicine commonly used has effects such as heat-clearing and toxic substances removing, dredge the meridian passage, broad-spectrum antiseptic and antiviral, and " Chinese medicine antibiotic ", " title of antibacterial green element are arranged; Has the YIN nourishing and the production of body fluid promoting effect Radix Ophiopogonis; Spica Prunellae bitter in the mouth, property are hot, and be cold, has mass dissipating and swelling eliminating, controls that scrofula, goiter, acute mastitis swell and ache, the function and the effect of thyromegaly, tuberculous lymphadenitis and cyclomastopathy; And the modern pharmacy theory adopts following technical scheme to realize:
The present invention treats hypothyroid medicine; It is that Radix Codonopsis 15-25%, Radix Astragali 15-25%, Flos Lonicerae 25-40%, Radix Ophiopogonis 15-30%, Spica Prunellae 10-20% with following percentage by weight is raw material, the oral liquid or decoction or granule or capsule or tablet or pill or syrup or mixture or the powder that make with conventional method.
Above-mentioned said raw material, preferred raw material weight percentage ratio be Radix Codonopsis 17-23%, Radix Astragali 17-25%, Flos Lonicerae 28-35%, Radix Ophiopogonis 17-23%, Spica Prunellae 10-15%.
The specific embodiment:
Embodiment 1, choose Radix Codonopsis 25 gram, the Radix Astragali 25 grams, Flos Lonicerae 25 grams, Radix Ophiopogonis 15 gram, Spica Prunellae 10 grams are raw material, make oral liquid with conventional method.
Instructions of taking: consumption a: 20mg, one day twice.Usage: oral.The normal back of thyroid function dosage reduces by half, and is normal like the first merit after half amount is taken one month, on the basis of half amount, reduces by half the normal drug withdrawal of first merit after January again.
Embodiment 2, according to embodiment 1, wherein Radix Codonopsis 15 gram, the Radix Astragali 15 grams, Flos Lonicerae 40 grams, Radix Ophiopogonis 15 gram, Spica Prunellae 15 grams.
Embodiment 3, according to embodiment 1, wherein Radix Codonopsis 15 gram, the Radix Astragali 15 grams, Flos Lonicerae 25 grams, Radix Ophiopogonis 30 gram, Spica Prunellae 15 grams.
Embodiment 4, according to embodiment 1, wherein Radix Codonopsis 15 gram, the Radix Astragali 15 grams, Flos Lonicerae 25 grams, Radix Ophiopogonis 25 gram, Spica Prunellae 20 grams.
Embodiment 5, according to embodiment 1, wherein Radix Codonopsis 20 gram, the Radix Astragali 20 grams, Flos Lonicerae 30 grams, Radix Ophiopogonis 20 gram, Spica Prunellae 10 grams.
Concrete case:
1, Sun Shihua/woman is 51 years old
1) before the treatment: the enlargement of thyroid II degree, quality hardening, weak, hypersomnia, be afraid of cold, brothers' wood expands inspection serum first merit, T3:57.1, T4＜1, TSH＞75, TM:49.1, TG:71.7.
2) treatment back: take medicine oral liquid of the present invention, transference cure after two weeks; Take medicine month serum first merit T3:81.6, T4:8.1, TSH:3.6, TM 23.2, TG:31, thyroid dwindles, the more preceding deliquescing of quality, it is normal to follow up a case by regular visits to 7 years first merits.
2, Zhang Yanrong/woman is 35 years old
1) before the treatment: the enlargement of thyroid II degree, quality hardening, weak, pale complexion edema, sleepy hypersomnia, brothers' wood expand, amenorrhea March, inspection serum first merit, T3:71.4, T4:3.7, TSH＞75, TM:60.4, TG:72.6.
2) treatment back: take medicine oral liquid of the present invention, two week the back above-mentioned symptoms obviously alleviate month serum first merit T3:107, T4:4.9, TSH:11.9, TM:31.3, TG:26.1; Two months transference cures, the menstruation compound tides, the thyroid size recovers normal, and the hypothyroidism soup amount of reducing by half is taken; The normal drug withdrawal of first merit in three months, it is normal to follow up a case by regular visits to 5 years first merits.
3, Wang Fuxiang/woman is 25 years old
1) before the treatment: thyromegaly, quality hardening, weak, hypersomnia, be afraid of cold, constipation abdominal distention, brothers' wood expands inspection serum first merit, T3:53.9, T4:1.6, TSH＞75, TM:57, TG:59.6.
2) treatment back: take medicine oral liquid of the present invention, above-mentioned symptom obviously alleviates after two weeks; Month serum first merit T3:95.5, T4:8.8, TSH:1.89, TM:31.1, TG:27.9, the thyroid of enlargement obviously dwindles.
4, Sun Xiuli/woman is 35 years old
1) before the treatment: thyromegaly, quality hardening, weak, hypersomnia, be afraid of cold, brothers' wood expands, constipation, menorrhagia the year before, the back amount is less, delay inspection serum first merit, T3:58.3, T4:4.4, TSH:60.6 menstrual period.
2) treatment back: take medicine oral liquid of the present invention, above-mentioned symptom obviously alleviated in one month, serum first merit T3:83.2, T4:6.9, TSH:15.2; Took medicine T3:90.5, T4:8.1, TSH:2.32 two months; Hypothyroidism transference cure first merit was normal in three months, and following up a case by regular visits to 3 years, all are normal.
5, paid Xiao Hong/woman 17 years old
1) before the treatment: thyromegaly 1 year, sense hypomnesis, easy catching a cold, thyroid color ultra show thyroid essence diffuse lesion, enlargement, inspection serum first merit, T3:65.9, T4:1.8, TSH＞75, TM:56.5, TG:73.9.
2) treatment back: take medicine oral liquid of the present invention, the thyroid outward appearance was dwindled in one month, serum first merit T3:60.5, T4:7.6, TSH:2.34, TM:39.5, TG:52.0; Take medicine February, the first work recovery is normal, TM:14.1, TG:12.7.
6, Jiang Hemei/woman is 15 years old
1) before the treatment: thyromegaly, weak, be afraid of cold inspection serum first merit, T3:40.0, T4:1.6, TSH＞75.
2) treatment back: take medicine oral liquid of the present invention, the thyroid outward appearance was dwindled in one month, serum first merit T3:163.0, T4:7.4, TSH:6.07; Take medicine February, T3:169.1, T4:9.6, TSH:2.98, the first work recovery is normal.
7, Wang Yanxia/woman is 33 years old
1) before the treatment: the enlargement of thyroid II, too fat to move obesity, pale complexion edema due to deficiency, xerosis cutis, alopecia, anorexia abdominal distention, constipation; Fatigue and weakness, easy catching a cold, apathy, hypomnesis; Inspection serum first merit, T3:42.1, T4:1.4, TSH＞75, TM:25.9, TG39.9.
2) treatment back: take medicine oral liquid of the present invention, the thyroid outward appearance was dwindled in one month, serum first merit T3:93.1, T4:7.7, TSH:2.31, TM:19.1, TG:24.5; But the February first work recovery of taking medicine is normal.
8, Xiong Huiye/woman is 16 years old
1) before the treatment: thyromegaly, quality hardening, weak, hypersomnia, be afraid of cold, constipation abdominal distention, hypomnesis, inspection serum first merit, T3:59.2, T4:3.8, TSH:71, TM:31.2, TG:40.8.
2) treatment back: take medicine oral liquid of the present invention, above-mentioned symptom obviously alleviates after two weeks; Month serum first merit T3:119.3, T4:7.1, TSH:2.26, the thyroid of enlargement obviously dwindles.
9, Zhou Zhili/woman is 37 years old
1) before the treatment: thyromegaly, cyclomastopathy, inspection serum first merit, T3:63, T4:4.1, TSH:64.
2) treatment back: take medicine oral liquid of the present invention, the thyroid outward appearance was dwindled in one month, serum first merit T3:109.1, T4:7.2, TSH:4.87; The February first work recovery of taking medicine is normal, the cyclomastopathy recovery from illness.
10, Wang Xia/woman is 30 years old
1) before the treatment: weak over the past half year, abdominal distention, thyromegaly, brothers' wood expand, inspection serum first merit, T3＜40, T4:1.1, TSH＞75.
2) treatment back: take medicine oral liquid of the present invention, the thyroid outward appearance was dwindled in one month, serum first merit T3:108.1, T4:4.7, TSH:41.26; Take medicine February; T3:143.0, T4:9.2, TSH:2.93, three the first quarter moon first work recovery of taking medicine are normal.
11, Bao Wenxin/woman is 30 years old
1) before the treatment: thyromegaly, quality hardening, weak, hypersomnia, be afraid of cold, brothers' wood expands, constipation, MBV are few, delay inspection serum first merit, T3:44.3, T4＜1, TSH＞75 menstrual period.
2) treatment back: take medicine oral liquid of the present invention, above-mentioned symptom obviously alleviated in one month, serum first merit T3:82.3, T4:7.4, TSH:15.2; Two months, T3:101.5, T4:8.8, TSH:2.32; Hypothyroidism transference cure first merit was normal in three months, and following up a case by regular visits to 5 years, all are normal.
12, Liu Changhua/woman is 26 years old
1) before the treatment: the enlargement of thyroid II, pale complexion edema due to deficiency, anorexia abdominal distention, constipation, fatigue and weakness, easy catching a cold, apathy, hypomnesis, inspection serum first merit, T3＜40, T4＜1, TSH＞75, TM:34.9, TG:50.5.
2) treatment back: take medicine oral liquid of the present invention, the thyroid outward appearance was dwindled in one month, serum first merit, T3:93.1, T4＜1, TSH＞75, TM:33.9, TG:45.5; The serum first merit in March of taking medicine, T3:98.5, T4:6.9, TSH:4.1, TM:31.2, TG:26; The first work recovery was normal in six months.
Annotate: T3 representes free triiodothyronine in the preceding text, normal reference value 60-181; T4 representes thyroxine, and normal reference value is 4.5-10.9; TSH representes thyrotropin, and normal reference value is 0.35-5.5; TG representes TGA, normal reference value is＜and 15%; TM represents TMA, normally be＜30%.
Data and method
1.1 physical data
Use medicine oral liquid of the present invention over nearly 10 years, the hypothyroidism of treatment is received satisfied effect, and is all effective to various hypothyroidism.But it is more remarkable observe to find that the Hashimoto disease hypothyroidism is gone the effect of hormone replacement therapy.This time statistics is taken in case 106 examples, male 33 examples, women 73 examples, minimum 7 years old of age, maximum 64 years old, average 32.5 years old.Struma lymphomatosa secondary hypothyroidism 91 examples, behind the thyroid operation or iodine 131 treatment back secondary hypothyroidism 15 examples, subacute thyroiditis prognosis 7 examples.
Cardinal symptom has cervical region to increase thick or thyromegaly 89 examples, weak or asthenia 67 examples, and cervical region is tightly restrainted sense of discomfort 43 examples, and cervical region aches 11 examples; 35 examples of being afraid of cold, sleepy hypersomnia 41 examples, face or limbs edema 16 examples, constipation 46 examples; Merge cyclomastopathy 51 examples, numb hand and foot 36 examples, overcast 18 examples of voice, low 11 examples of emotion, menostaxis 3 examples; Pigmentation 21 examples, hypopnea 5 examples, weight increase 29 examples, alopecia 14 examples, slow 11 examples of heart rate.Medical history is the longest 30 years, and is the shortest 15 days.
Lab testing shows that 106 routine patient T3 obviously reduce by 49 examples, account for 47%; T4 reduces by 57 examples, accounts for 74%; TSH 106 examples that raise account for 100%; 72 examples detect TMAB, TGAB, and TMAB 45 examples that raise wherein account for 63%, TGAB raises 43 examples, accounts for 61%.34 examples are not TMAB, TGAB detects.
1.2 result
Therapeutic outcome is divided into recovery from illness, improvement, does not heal and increases the weight of.Symptom and sign disappears, the lab testing result is normal, observes and does not have recurrence in 6 months for fully recovering; Symptom and sign obviously alleviates, and the lab testing result is tending towards normally, observes not have in 2 months and increases the weight of to taking a turn for the better; Symptom and sign and lab testing result do not have obvious improvement, or improve in back 2 months recurrence for not healing; Symptom and sign increases the weight of, and T3, T4 further are reduced to and increase the weight of.Recovery from illness 79 examples account for 75% among the 106 routine patients, and 23 examples that take a turn for the better account for 22%, and invalid 4 examples account for 3%, are the patient that hormone replacement therapy is crossed behind the iodine therapy.Do not have patient the state of an illness to occur and increase the weight of, effective percentage 97%.
Find out that more than medicine of the present invention can improve endocrine function, thereby fundamentally treat hypothyroidism through regulating immunity of organisms, and patient needn't be taken medicine throughout one's life; This therapy no pain, have no side effect, economical convenient, make patient's parathyroid tissue full of vitality again, thereby keep normal physiological function.
Claims (2)
1. treat hypothyroid medicine for one kind; It is characterized in that it is that Radix Codonopsis 15-25%, Radix Astragali 15-25%, Flos Lonicerae 25-40%, Radix Ophiopogonis 15-30%, Spica Prunellae 10-20% with following percentage by weight is raw material, the oral liquid, granule, capsule, pill or the powder that make with conventional method.
2. medicine according to claim 1, it is characterized in that said raw material weight percentage ratio be Radix Codonopsis 17-23%, Radix Astragali 17-25%, Flos Lonicerae 28-35%, Radix Ophiopogonis 17-23%, Spica Prunellae 10-15%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102067008A CN101843842B (en) | 2010-06-14 | 2010-06-14 | Medicament for treating hypothyroidism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102067008A CN101843842B (en) | 2010-06-14 | 2010-06-14 | Medicament for treating hypothyroidism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101843842A CN101843842A (en) | 2010-09-29 |
| CN101843842B true CN101843842B (en) | 2012-06-27 |
Family
ID=42768780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102067008A Active CN101843842B (en) | 2010-06-14 | 2010-06-14 | Medicament for treating hypothyroidism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101843842B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357191B (en) * | 2011-10-31 | 2013-06-05 | 尹洁 | Pharmaceutical composition for treating hashimoto disease |
| CN110721230B (en) * | 2019-11-12 | 2021-09-17 | 正大青春宝药业有限公司 | Traditional Chinese medicine composition for treating hashimoto's thyroiditis and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085248A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine for treating hypothyroidism |
| CN101152400A (en) * | 2007-09-15 | 2008-04-02 | 尹克华 | Traditional Chinese medicine for treating simple goiter |
-
2010
- 2010-06-14 CN CN2010102067008A patent/CN101843842B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085248A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine for treating hypothyroidism |
| CN101152400A (en) * | 2007-09-15 | 2008-04-02 | 尹克华 | Traditional Chinese medicine for treating simple goiter |
Non-Patent Citations (2)
| Title |
|---|
| 曾秀池.中药抗衰老机理浅识.《实用中医药杂志》.2006,第22卷(第11期),712-713. * |
| 石磊等.亚急性甲状腺炎中医药治疗概况.《新中医》.2001,第33卷(第08期),69-70. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101843842A (en) | 2010-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102743501B (en) | A kind of prescription for the treatment of qi-deficiency type uterine prolapse | |
| CN102657821B (en) | Drug for treating ovarian cyst | |
| CN105412858A (en) | Syrup and preparation method thereof | |
| CN101843842B (en) | Medicament for treating hypothyroidism | |
| CN1876066A (en) | A medicine for treating impotence and preparation method thereof | |
| CN103990078A (en) | Traditional Chinese medicine composition for treating jaundice hepatitis | |
| CN101152436A (en) | Traditional Chinese medicine for treating chronic pharyngitis | |
| CN102579788B (en) | Medicinal composition for treating peptic ulcer | |
| CN105435048A (en) | Traditional Chinese medicine for treatment of thyroid tumor | |
| CN104689239A (en) | Traditional Chinese medicine composition for treating cholelithiasis and preparation method thereof | |
| CN103181945B (en) | The purposes of Semen Luffae | |
| CN1205990C (en) | Medicine for treating diabets mellitus | |
| CN103223052A (en) | Traditional Chinese medicine used for treating prostatitis | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN111228400B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof | |
| CN102133358B (en) | Oral administration Chinese medicinal capsules for treating tumors | |
| CN103417763B (en) | One treats osteoporotic pharmaceutical composition and its production and use | |
| CN102698144B (en) | Traditional Chinese medicine composition for treating gasteremphraxis | |
| CN106344818A (en) | Method for preparing traditional Chinese medicine composition for treating migraine | |
| CN105663772A (en) | Drug for treating diabetes mellitus | |
| CN104825837A (en) | Traditional Chinese medicine for treating hypothyroidism | |
| CN102698219A (en) | Drug for treating hyperplasia of prostate and preparation method thereof | |
| CN103933390B (en) | Traditional Chinese medicinal preparation for treating breast cystic hyperplasia | |
| CN101450156A (en) | Traditional Chinese medicine composition for treating female genitalia leukoplakia | |
| CN102836343B (en) | Medicine for colon nursing and colitis treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RUGAO XIAYUAN HOSPITAL Free format text: FORMER OWNER: LIU AIWU Effective date: 20141231 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276003 LINYI, SHANDONG PROVINCE TO: 226500 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141231 Address after: 226500, Jiangsu, Rugao City, the original town under the original community neighborhood committee Patentee after: Rugao lower primary hospital Address before: 276003 Linyi people's Hospital, 27 east section, Linyi, Shandong, Jiefang Road Patentee before: Liu Aiwu |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180105 Address after: 276003 Linyi people's Hospital, 27 east section, Linyi, Shandong, Jiefang Road Patentee after: Liu Aiwu Address before: 226500, Jiangsu, Rugao City, the original town under the original community neighborhood committee Patentee before: Rugao lower primary hospital |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180806 Address after: 410205 207 Rui long road, hi tech Zone, Changsha, Hunan Patentee after: Changsha Tonghui Medicine Technology Co., Ltd. Address before: 276003 Linyi City People's Hospital, 27 Jiefang Road east section, Linyi, Shandong Patentee before: Liu Aiwu |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201216 Address after: 415900 inside the incubator building of bamboo tablet neighborhood committee, Hanshou high tech Industrial Park, Changde City, Hunan Province Patentee after: HANSHOU KANGYUN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 410205 207 Rui long road, hi tech Zone, Changsha, Hunan Patentee before: Changsha Tonghui Medicine Technology Co.,Ltd. |